Physician profile
William Evans
NPI 1619913761
$29,468.82
in general payments reported to CMS, 2019-2025
67 companies · $4,230 in 2025
The $4,230 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,602 · 2020: $3,010 · 2021: $4,135 · 2022: $4,258 · 2023: $4,117 · 2024: $5,116 · 2025: $4,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,305.54 |
| Education | $157.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,068.15 | 2021-2025 | |
| Ucb, INC. | $2,282.87 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $1,889.24 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $1,788.29 | 2019-2025 | Nuplazid |
| Emd Serono, INC. | $1,629.50 | 2019-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $1,170.90 | 2019-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $1,092.75 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genentech USA, INC. | $1,079.24 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Alexion Pharmaceuticals, INC. | $1,043.02 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $997.21 | 2019-2025 | |
| Sk Life Science, INC. | $933.60 | 2020-2025 | |
| Allergan, INC. | $886.02 | 2019-2022 | |
| Biogen, INC. | $794.76 | 2019-2025 | Vumerity, Tysabri |
| Lundbeck LLC | $780.01 | 2019-2025 | Vyepti |
| Horizon Therapeutics Plc | $613.84 | 2021-2023 | Uplizna |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.